Sisram Medical, a Israeli subsidiary of Shanghai Fosun Pharmaceutical, and which manufactures medical aesthetics devices, has priced its HK$977 million (US$125 million) IPO on the Hong Kong Stock Exchange at the low end of guidance.
Sisram has sold 110 million shares or around 25% of its total share capital at HK$8.88 per share. This is at the bottom end of the HK$8.88-HK$12.35 per share guidance. Also included are 22 million secondary shares.
This gives the company a forward P/E ratio of 16.5.
The first day of trading is 19 September.
Joint sponsors are CICC and Jefferies.